Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TA-650 in comparison with
a control drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in patients with
Kawasaki disease refractory to initial therapy with Intravenous Immunoglobulin (IVIG). The
pharmacokinetics of TA-650 is also examined.